Erytech Pharma today presents poster entitled about A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma, in an event in San Francisco.
Currently the trial is approved for patients participation in eight selected European countries, and enrolling patients in 21 clinical sites.
Erytech said that overall, eryaspase was well tolerated and did not appear to increase the toxicity of the chemotherapy.
“Patients with advanced pancreatic cancer need new treatment options. As global co-Principal Investigator, I am delighted with the rapid set-up of the study. The Trial-in-Progress poster demonstrates that we are making excellent progress toward the initiation of over 100 centers for TRYbeCA-1,” commented Dr. Manuel Hidalgo-Medina, medical oncologist at Beth Israel Deaconess Medical Center in Boston and professor of medicine at Harvard Medical School.
Iman El-Hariry, Chief Medical Officer, said.“The results from our landmark Phase 2b study are highly promising and underscore the importance of targeting tumor metabolism pathways in pancreatic cancer. We are hopeful to provide a novel treatment modality for this highly unmet medical need. We are very pleased that the Phase 3 study is making excellent progress and patient enrollment continues as planned. Our enrolled patients mark the initiation of the trial in Europe. We expect investigator sites in the United States will begin enrolling this quarter.”